• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ORGO

ORGO

Organogenesis Holdings Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD2.33

+0.09 (+4.02%)

Rating:C+

Company Profile

CEO

Gary S. Gillheeney

IPO Date

2017-01-05

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$2.23

Prev. Close

$2.24

Day Low

$2.21

Day High

$2.37

52W Low

$2.04

52W High

$7.08

Market Cap

$0.30B

Volume

0.81M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

15.0%

Avg Negative

6.9%

Avg Neutral

78.0%

News Feed

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2021 Financial Results on August 9, 2021

GlobeNewsWire·7/2/2021·↑ positive

Why Organogenesis Holdings Blasted 7.7% Higher Today

The Motley Fool·5/27/2021·↑ positive

Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/11/2021·↓ negative

Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates

Zacks Investment Research·5/10/2021·↑ positive

CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results

GlobeNewsWire·5/10/2021·↓ negative

Organogenesis Holdings: Q1 Earnings Insights

Benzinga·5/10/2021·↑ positive

Organogenesis Appoints Jon Giacomin to Board of Directors

GlobeNewsWire·5/10/2021·↓ negative

Earnings Outlook for Organogenesis Holdings

Benzinga·5/7/2021·↓ negative

Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting

GlobeNewsWire·5/6/2021·↑ positive

Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·3/16/2021·↓ negative